February 11, 2008
BSX Enrolls First Patient In European Stent Study
By Cory Hopkins
Natick medical device manufacturer Boston Scientific has enrolled its first patient in a European study of its newest drug-eluting coronary stent, known as PROMUS.
The study will compare the effectiveness of BSX's stent to competing devices from Johnson & Johnson and Medtronic.
The PROMUS stent is essentially a renamed version of Abbott Laboratories' XIENCE V drug-eluting coronary stent, which will be sold under the Boston Scientific name under a previously announced agreement between the two companies.
The PROMUS stent will be compared to the Endeavor drug-eluting stent from Medtronic and Johnson & Johnson's Cypher stent.
The study will enroll up to 2,500 patients. Half will receive the PROMUS stent, while the other half will receive either the Cypher or Endeavor stents. The study will catalog the rate of major cardiac events associated with each stent over a period of one year.
The study will compare the effectiveness of BSX's stent to competing devices from Johnson & Johnson and Medtronic.
The PROMUS stent is essentially a renamed version of Abbott Laboratories' XIENCE V drug-eluting coronary stent, which will be sold under the Boston Scientific name under a previously announced agreement between the two companies.
The PROMUS stent will be compared to the Endeavor drug-eluting stent from Medtronic and Johnson & Johnson's Cypher stent.
The study will enroll up to 2,500 patients. Half will receive the PROMUS stent, while the other half will receive either the Cypher or Endeavor stents. The study will catalog the rate of major cardiac events associated with each stent over a period of one year.
WBJ Web Partners
Most Recent
Most Recent
0 Comments